Millennium Partners sells 2 million shares of MiddleBrook Pharmaceuticals

By Lisa Kerner

Charlotte, N.C., July 3 - Millennium Partners, LP reported the sale of 2 million shares of MiddleBrook Pharmaceuticals, Inc. on July 2 priced from $1.37 to $1.42 each in a schedule 13D filed with the Securities and Exchange Commission.

The investor beneficially owns 3.8% of the company's common stock.

In February, MiddleBrook Pharmaceuticals said it retained Morgan Stanley to assist the company and its co-adviser, Pacific Growth Equities, LLC, in the ongoing review of strategic alternatives.

It was previously reported that the company is considering a range of alternatives including execution of MiddleBrook's operating plan, the sale of the company or its assets and collaborative agreements.

MiddleBrook is a Germantown, Md., pharmaceutical company specializing in anti-infective drug products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.